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Abstract
Viral infections can be broadly divided into infections that are cleared from the host
(acute) and those that persist (chronic). Why some viruses establish chronic infections
while other do not is poorly understood. One possibility is that the host’s immune response
is impaired during chronic infections and is unable to clear the virus from the host.
In this report we use a recently proposed framework to estimate the per capita killing
efficacy of CD8+ T cells, specific for the MT389 epitope of polyoma virus (PyV), which
establishes a chronic infection in mice. Surprisingly, the estimated per cell killing efficacy
of MT389-specific effector CD8+ T cells during the acute phase of the infection was very
similar to the previously estimated efficacy of effector CD8+ T cells specific to lymphocytic
choriomeningitis virus (LCMV-Armstrong), which is cleared from the host. We also find
that during the chronic phase of the infection the killing efficacy of PyV-specific CD8+ T
cells was only half of that of cells in the acute phase. This decrease in the killing efficacy
is again surprisingly similar to the change in the killing efficacy of LCMV-specific CD8+
T cells from the peak of the response to the memory phase. Interestingly, we also find
that PyV-specific CD8+ T cells in the chronic phase of the infection require lower doses
of antigen to kill a target cell. In summary, we find little support for the hypothesis that
persistence of infections is caused by inability of the host to mount an efficient immune
response, and that even in the presence of an efficient CD8+ T cell response, some viruses
can still establish a persistent infection.
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1 Introduction
CD8+ T cells play an important role in controlling growth of viral infections both in mice and
in humans by multiple mechanisms including killing of virus-infected cells and producing anti-
viral cytokines (1, 2). Following acute viral infections, CD8 T cells follow a defined program of
expansion, differentiation and contraction that results in the clearance of the virus within 1 to
2 weeks of the infection (3, 4, 5). During the expansion phase, CD8+ T cells differentiate into
effectors that possess multiple functions and are very efficient killers in vivo (6, 7, 8). Although
during a chronic viral infection such LCMV clone 13 infection of mice CD8+ T cells follow a
similar program of expansion and contraction (9), control of the virus is limited (2). Persistent
viral load progressively leads to exhaustion of antigen-specific CD8+ T cells which over time
lose various effector functions such as production of IL-2 and TNF-α (2). A similar progressive
disfunction of antigen-specific CD8+ T cells has been observed during HIV infection (10).
Why some infections are cleared while others persist is unknown and likely to be different
for different infections. One hypothesis is that viruses that persist may elicit T cell responses of
inadequate quality that are unable to control viral growth during acute phase of the infection.
Indeed, infection of mice with LCMV clone 13 (that persists) elicits CD8+ T cell response of
a lower magnitude than during LCMV-Armstrong infection (that is cleared) and this could
be a part of the reason why LCMV clone 13 persists in mice (9). Another potential reason
could be a low effector to target ratio induced during the infection with the rapidly replicating
LCMV clone 13 (11). Finally, a lower efficiency of virus-specific CD8+ T cells induced during
a chronic viral infection as compared to T cells during acute infections may be responsible for
viral persistence. There have been no studies that attempted to discriminate between different
mechanisms for viral persistence and to the best of our knowledge there have been no studies
that have measured the in vivo killing efficacy of CD8+ T cells during chronic viral infections.
Using a recently developed method of in vivo cytotoxicity (12, 13, 14, 15, 16), we investigate
whether infection of mice with polyoma virus (PyV) that causes a persistent infection elicits
a CD8+ T cell response of a low killing efficacy and whether this killing efficacy changes from
the acute to chronic phase of the infection. Unexpectedly, we found that the in vivo killing
efficacy of PyV-specific CD8+ T cells at the peak of the immune response is very similar to that
of LCMV-Armstrong-specific CD8+ T cells obtained in our previous study (8). This argues
that inability of CD8+ T cell response to clear PyV infection in the acute phase is not due
to a low killing efficacy of antigen-specific T cells. Furthermore, during the chronic phase of
the infection, PyV-specific CD8+ T cells did not lose their ability to kill even months after the
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primary infection, being only 2 fold less efficient killers than effectors present at the peak of the
immune response. Thus, even in the presence of an efficient CD8+ T cell response, PyV is able
to establish a persistent infection in mice, and it is likely that other viral and/or host factors
play in important role in this process.
2 Material and Methods
2.1 Data
The method of measuring cytotoxicity of CD8+ T cells in vivo has been described in detail
elsewhere (e.g., (7, 17)). In this report, we reanalyze recently published data on killing of
peptide-pulsed splenocytes by polyoma virus (PyV) specific CD8+ T cells during acute and
chronic phases of the PyV infection of C3H/HeN mice (16). The reader is referred to the
original publication for more detail. In short, target splenocytes were pulsed with the MT389
peptide of PyV or were left unpulsed. The peptide MT389 was chosen because it elicits the
dominant CD8+ T cell response in H-2k (C3H) mice (18). Cells were transferred into syngeneic
mice either infected with PyV 7 days before (“acute” phase), or into mice controlling PyV
infection (days 35-175 post infection, “chronic” phase). At day 7 after the infection, the CD8+
T cell response to PyV reaches its peak, and by 30 to 40 days after the infection, the CD8+
T cell response largely contracts (19). At different times after the transfer of target cells
(15 min, 30 min, 1 hour, 2 hours, and 4 hours), spleens were harvested, and the number of
pulsed and unpulsed targets, splenocytes, and peptide-specific CD8+ T cells was measured.
To investigate how the killing efficacy of MT389-specific CD8+ T cells may be affected by
the peptide concentration, in a series of experiments target splenocytes were pulsed with 5
different concentrations of the MT389 peptide (10, 1, 0.1, 0.01, and 0.001 µM) and killing of
peptide-pulsed targets was measured as described above.
To estimate the per capita killing efficacy of MT389-specific CD8+ T cells we used the av-
erage frequency of these cells in spleens of PyV-infected mice. Our previous analyses suggested
that the frequency of LCMV-specific CD8+ T cells in an individual mouse bears little informa-
tion on the number of target cells killed in the same mouse (Ganusov at al. in preparation). The
use of cell frequencies, rather than cell numbers, is also supported by our previous work (8) and
follows from general physical principles because killing occurs in a solid organ such as spleen
(6). In experiments of Byers et al. (16), using average frequencies of MT389-specific CD8+ T
cells in mice in the acute or the chronic phase rather than values measured in individual mice
also gave a better fit of the data (results not shown). As in our previous work (8), this is likely
because measurements of CTL frequencies were noisy and poorly correlated with the number of
targets killed (results not shown). Therefore, we used the average frequency of MT389-specific
3
CD8+ T cells in the spleen for fitting the data. In the acute phase f = 1.13% (with standard
deviation 0.21%), and in the chronic phase was f = 0.79% (with standard deviation 0.15%).
We have previously found that for LCMV-infected mice, the rate of recruitment of target
cells into the spleen was correlated with the spleen size (7). For PyV-infected mice, a similar
correlation was found although it was not statistically significant (results not shown). Therefore,
to simplify the analysis here we assumed that recruitment of target cells into the spleen occurs
at the same rate σ in all mice (see also below).
2.2 Mathematical model for the cytotoxicity in vivo assay
As we have previously described (7), changes in the number of unpulsed and peptide-pulsed
targets in the mouse spleen are given by the following equations:
S(t) =
c
d− ǫ
[
e−ǫt − e−dt
]
, (1)
T (t) =
c
(ǫ+K − d)
[
e−dt − e−(ǫ+K)t
]
, (2)
where d = σ + ǫ + δ is the rate of removal of cells from the blood, σ and δ are the rates of
recruitment of targets from the blood into the spleen or elsewhere, respectively, ǫ is the rate
of preparation-induced cell death, c = SB(0)σ, and SB(0) = 5 × 10
6 is the initial number of
targets adoptively transferred into mice. Dividing eqn. (2) by (1) we arrive at the experimentally
measured ratio of peptide-pulsed to unpulsed targets, R(t) = T (t)/S(t)
R(t) =
(d− ǫ)
(ǫ+K − d)
[
e−dt − e−(ǫ+K)t
e−ǫt − e−dt
]
. (3)
This equation can used to estimate the death rate of pulsed targets K due to CD8+ T cell
mediated killing from the changes in the ratio R over time (7, see also Figure 1). To estimate
the per capita killing efficacy of PyV-specific CD8+ T cells we let K = kf where k is the per
capita killing efficacy and f is the frequency of MT389-specific CD8+ T cells in the mouse
spleen. Using adoptive transfer of different numbers of LCMV-specific effectors or memory
T cells we have recently shown that killing of peptide-pulsed targets is proportional to the
frequency of effector CD8+ T cells in the spleen, but killing saturates at high frequencies of
memory CD8+ T cells (8). For PyV, no similar adoptive transfers have been performed, and
therefore we do not know if the death rate of targets saturates with the increasing frequency of
PyV-specific effector and memory CD8+ T cells. This will be a subject of an additional study.
For the following analysis we thus assume that death rate of peptide-pulsed targets K in the
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spleen is proportional to the average frequency of epitope-specific CD8+ T cells in the acute or
chronic phases of the infection.
In our analysis, we also estimate the maximal (Kmax) and minimal (Kmin) death rate of
peptide-pulsed targets due to CD8+ T cell mediated killing from the in vivo cytotoxicity ex-
periments (7). Kmax is estimated by solving the following transcendental equation
Kmax =
(1− e−Kmaxt)
Rt
, (4)
and Kmin is estimated from
Kmin = −
logR
t
. (5)
where R is the ratio of the frequency of peptide-pulsed to unpulsed targets in the spleen at time
t after target cell transfer. The per capita killing efficacy of CD8+ T cells k is then calculated,
assuming the mass-action killing term (see above) by dividing the death rate of peptide-pulsed
targets K by the frequency of peptide-specific CD8+ T cells in the mouse spleen f .
The dependence of the killing efficacy of CD8+ T cells on the peptide concentration used
to pulse target cells was taken in the form of a Hill function
k =
kˆpn
hn + pn
, (6)
where kˆ is the maximal killing efficacy of MT389-specific CD8+ T cells, p is the peptide concen-
tration used to pulse target cells, h is the peptide concentration at which killing is half-maximal,
and n is the power of the Hill function.
2.3 Statistics
In our previous study (7), we assumed that errors in measuring the number of unpulsed targets
in the spleen and in the ratio of the frequency of peptide-pulsed to unpulsed targets peptide-
pulsed targets were of a similar magnitude. In PyV-infected mice this was not the case, since
there was a significantly larger error in estimating the number of targets recruited than the
percent of targets killed (e.g., see Figure 1). Therefore, we used a general likelihood approach
to fit the data on recruitment of targets to the spleen and killing of peptide-pulsed targets
in the spleen (see Supplementary Information). Data on recruitment and on killing were log-
transformed but were assumed to have different distribution of errors (with standard deviations
s1 and s2, respectively). In general this resulted in well-behaved and normally distributed resid-
uals except of the data when targets were pulsed with a low peptide concentration. The latter
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fits resulted in a skewed distribution of the residuals (results not shown). Discrimination be-
tween different models was done using either the likelihood ratio test (LRT) or F-test for nested
models (20, 21). Confidence intervals (CIs) were calculated by bootstrapping the data with
1000 simulations (22). Fittings were done in Mathematica 5.2 using the routine FindMinimum.
3 Results
3.1 Estimation of the killing efficacy of polyoma virus specific CD8+
T cells
We have previously developed a mathematical model to estimate the death rates of peptide-
pulsed targets in vivo due to CD8+ T cell mediated killing and the per capita killing efficacy
CD8+ T cells (7, 8). Here, we applied this model to estimate the per capita efficacy of the
immunodominant polyoma virus (PyV)-specific CD8+ T cell response at killing target spleno-
cytes, pulsed with MT389 peptide during the acute (day 7) or chronic (days 32-175) phases of
the PyV infection of mice (19). The model described the data well (Figure 1) and estimated
that half of peptide-pulsed targets are eliminated in 15 minutes in acutely infected mice and
in 47 minutes during the chronic phase of the infection. Both rates are surprisingly similar
to those obtained for targets expressing peptides from LCMV Armstrong (7). Even more sur-
prising, the per capita killing efficacy of MT389-specific effectors (k ≈ 4.16 min−1) is very
similar to the estimates obtained in our previous study for effector CD8+ T cells, specific to
the NP396 (k = 5.5 min−1) or GP276 (k = 2.35 min−1) epitopes of LCMV (see Table 1 and
(8)). Similarly as in the previous studies (23, Ganusov et al. in preparation), we find that the
per capita killing efficacy of CD8+ T cells in the chronic phase of the infection was only twice
as low as the T cell efficacy during the acute infection (Figure 1). Such a change of the killing
efficacy from the peak of the CD8+ T cell response to the chronic phase was highly significant
(LRT: χ21 = 57.11, p≪ 0.01).
We found that recruitment of target cells into the spleen occurred at similar rates in the
acute and chronic phases of the PyV infection (Figure 1 and Table 1; χ22 = 1.80, p = 0.41).
Approximately 5% of all unpulsed targets accumulated in the mouse spleen at 4 hours of the
experiments that is consistent with previous estimates (7, 24). The half-life time of targets in
the blood as determined by the rate of removal of targets from the blood, d = δ + σ + ǫ, was
estimated at T1/2 ≈ 2 hours. This estimate is similar to an estimate obtained in our previous
study (7). Interestingly, in this study we did not find any evidence for the preparation-induced
death rate of targets (ǫ = 0, χ21 = 2.32, p = 0.13) that is in contrast with our previous
observation (7). Different methods of preparing single cell suspension in two laboratories and
type of infection may have contributed to the observed difference in estimates of this parameter.
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Figure 1: Estimating the efficacy of MT389-specific CD8+ T cells at killing targets, pulsed with a
high concentration of the peptide (≥ 1 µM), from the time series data. We fit the model prediction on
the total number of unpulsed targets in the spleen (panel A, see eqn. (1)) or the ratio of the frequency
of peptide-pulsed to unpulsed targets R (panel B, see eqn. (3)) to the data during acute (•) or chronic
(N) phases of the PyV infection of mice. Parameters providing the best fit of the model to the data
are given in Table 1. Recruitment of targets into the spleen occurred similarly during the acute and
chronic phases of the infection (χ22 = 1.80, p = 0.41). The half-life time of peptide-pulsed targets at
the peak of the MT389-specific CD8+ T cell response is only 15 minutes, while during the chronic
phase, half of MT389-expressing targets were eliminated in 47 minutes.
parameter acute chronic
σ, 10−4 min−1 3.96 (2.90–5.37)
δ, 10−3 min−1 4.92 (2.95–7.04)
k, min−1 4.16 (3.42–4.84) 1.90 (1.65–2.18)
Table 1: Parameter estimates obtained by fitting the data on killing of targets that were pulsed with
a high concentration (≥ 1µM) of the MT389 peptide. Here σ and δ is the rate of recruitment of
targets from the blood to the spleen or elsewhere, respectively, and k is the killing efficacy of MT389-
specific CD8 T cells during acute (left) or chronic (right) phase of the PyV infection of mice. The
parameter ǫ was fixed at 0 since it did not affect the quality of the model fit to data (LRT: χ21 = 2.32,
p = 0.13). The estimated standard deviation of the errors in the fit is s1 = 0.85 (0.64 − 1.04) and
s2 = 0.19 (0.13 − 0.23) (see Materials and Methods for detail). The provided 95% CIs were obtained
by bootstrapping the data with 1000 simulations.
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To further confirm our estimates of the killing efficacy of PyV-specific CD8+ T cells, we
calculated the minimal and maximal estimates of the killing efficacy at different times after
target cell transfer using a previously proposed protocol (7, see also Materials and Methods).
The estimates of the killing efficacy are fairly consistent for all time points analyzed for the
chronically infected mice but not for acutely infected mice (Figure S1 in Supplementary Infor-
mation). The latter is most likely due to errors associated with estimating the small number
of remaining targets at the end of the killing assay. Indeed, linear regression analysis suggests
that the estimate of the killing efficacy is increasing with the time since cell transfer (results not
shown). Importantly, there is a considerable overlap between estimates of the killing efficacy
of T cells in the acute and chronic phases of the PyV infection. This confirms the analysis
of the time series data that on average killing efficacy of the MT389-specific T cell response
in acute phase of the infection is only two fold lower than that of PyV-specific T cells in the
chronic phase (Figure 1 and Table 1). There was no significant change in the killing efficacy of
MT389-specific CD8+ T cells during the chronic phases of the infection (Figure 2) suggesting
that long-term exposure to a persistent infection need not result in the loss of in vivo effector
functions. This result is consistent with the previous observation that in chronic PyV infection,
CD8+ T cells are mainly maintained by the production of effector T cells from newly recruited
naive PyV-specific T cells (19). Nevertheless, this contrasts with the data on chronic LCMV
infection during which LCMV-specific CD8+ T cells lose their effector functions over time (25).
3.2 Killing efficacy at lower peptide concentrations
It has been known that the number of targets killed in the in vivo cytotoxicity assay depends
strongly on the amount of peptide used to pulse target cells (e.g., (16)). However, it has not
been investigated how this translates into the killing efficacy of CD8+ T cells and whether
there is a difference in the killing efficacy of T cells over the course of a chronic infection at low
peptide concentrations.
To investigate how the killing efficacy of CD8+ T cells depends on the concentration of the
peptide used to pulse target cells, we use two approaches. We estimated the per capita killing
efficacy of MT389-specific T cells for every mouse from single measurement of killing using eqn.
(4) and (5) (see Materials and Methods). As expected, we found that the killing efficacy of
CD8+ T cells was higher when targets were pulsed with a higher peptide concentration (Figure
3). Surprisingly, we find little difference in the killing efficacy of MT389-specific CD8+ T cells in
the acute and chronic phases of the infection when the peptide concentration was low. In fact, at
the lowest peptide concentration (0.001 µM), MT389-specific CD8+ T cells in the chronic phase
appeared to be more efficient at clearing peptide-pulsed targets than PyV-specific CD8+ T cells
in the acute phase of the infection (Figure 3). In contrast, at high peptide concentrations, T
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Figure 2: The per capita killing efficacy of PyV-specific CD8+ T cells does not change during the
chronic phase of the infection. We estimate the killing efficacy of MT389-specific CD8+ T cells from
the cytotoxicity assay by normalizing the death rate of peptide-pulsed targets Kmax by the average
frequency of epitope-specific CD8+ T cells in the spleen (see Materials and Methods). Bars show
the average estimate per time point. Regression slope is not significantly different from zero (F-
test, p = 0.17 with one outlier with a low estimate for kmax removed). The independence of the
killing efficacy of CD8+ T cells in the chronic phase of the infection from the time since infection was
further confirmed by fitting longitudinal killing data (as in Figure 1B) as the fit was not significantly
improved by assuming that killing efficacy was different for different days during the chronic phase of
the infection (F-test for nested models, F4,16 = 2.06, p = 0.13).
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Figure 3: Estimating the killing efficacy of the PyV-specific CD8+ T cells in acute and chronic phases
of the infection from single measurements of killing. Points represent the maximal killing efficacy of
MT389-specific CD8+ T cells, estimated for individual mice, and horizontal lines are averages for a
given peptide concentration. Solid lines show the fits of a Hill function given in eqn. (6) with n = 1 to
the estimated killing efficacies. The estimated parameters are: kˆ = 4.34 min−1, h = 0.12 µM (acute)
and kˆ = 1.91 min−1, h = 0.008 µM (chronic). Differences in kˆ and h for cells in the acute and chronic
phases of the infection remained if we used the minimal estimate of the killing efficacy (results not
shown)
cells in the acute phase were more efficient at killing targets than PyV-specific T cells in the
chronic phase as expected from the above analysis (e.g., see Table 1).
To verify these predictions we refitted the time series data on killing of targets pulsed with
peptides at different concentrations assuming that the killing efficacy of CD8+ T cells depends
on the amount of peptide that target cells present (see eqn. (6) in Materials and Methods). The
model described the data reasonably well (Figure 4) with the exception of the data with peptide
concentration 0.01 µM where the model underestimated the amount of killing (see also Figure
3). Interestingly, the model fits also predicted a lower half-saturation constant h (i.e., a higher
affinity to the antigen) of MT389-specific CD8+ T cells in the chronic phase of the infection
than that of cells in the acute phase (Table 2 and Figure S2 in Supplementary Information).
The fits also confirmed a higher killing efficacy of CD8+ T cells in the acute phase at high
concentrations of the MT389 peptide (Table 2).
4 Discussion
There is a limited understanding of why CD8+ T cell responses in some cases can control and
clear viral infections while in other cases they fail to do so. It was recently shown that the
initial effector to target ratio during acute phase of LCMV infection may determine whether the
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Figure 4: Estimating the efficacy of PyV-specific CD8+ T cells at killing target cells, pulsed with
different concentrations of peptide MT389, from the time series data. Points are the measured ratios of
the frequency of peptide-pulsed to unpulsed target cells, and lines show the fits of the model prediction
to the data. The data were fitted simultaneously assuming that the dependence of the killing efficacy
on the peptide concentration follows a Hill function (see eqn. (6)). Parameters providing the best fit
of the model to data are given in Table 2. Note that to show the fits and the data, we used different
scales on y-axes.
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parameter acute chronic
d, 10−3 min−1 5.83 (3.61–8.78)
kˆ, min−1 3.50 (2.93–4.04) 1.89 (1.58–2.16)
h, µM 0.19 (0.10–0.37) 0.08 (0.04–0.14)
Table 2: Parameter estimates obtained by fitting the data on killing of targets that were pulsed with
different concentrations of the MT389 peptide. The data were fitted as described in the legend of
Figure 4, assuming different maximal killing efficacies during acute and chronic phases of the infection
(kˆ) and different half-saturation constants (h, see eqn. (6) in Materials and Methods). Importantly,
the half-saturation constant was different for CD8+ T cells in acute and chronic PyV infection (F-test
for nested models, F1,61 = 4.7, p = 0.034). The shape parameter of the Hill function n was not
significantly different from 1 (F-test for nested models, F1,60 = 3.57, p = 0.064).
infection is cleared (high E/T ratio) or persists (low E/T ratio, (11)). Our results demonstrate
that in the case of PyV infection of mice, the failure to clear the infection is not due to a
reduced killing efficacy of PyV-specific CD8+ T cells. Instead we found that killing efficacy
of PyV-specific effectors is very similar to that of LCMV-specific CD8+ T cells that clear the
infection from mice within 7 days (26). Other mechanisms such as an ability to persist in a silent
form by expressing proteins at a low level, may have allowed PyV to escape the eradication
from infected mice. It will be interesting to investigate if infection of mice with other strains of
LCMV, some of which induce high levels of IL-10 (27, 28, 29), establish persistence by reducing
the killing efficacy of LCMV-specific CD8+ T cells and not necessarily due to a low ratio of
effectors to targets (11).
We found that PyV-specific CD8+ T cells during the chronic phase of the infection have a
lower half-saturation constant than T cells present at the peak of the immune response (Table
2 and Figure S2 in Supplementary Information). A lower half-saturation constant suggests that
these CD8+ T cells are more sensitive to lower quantities of the antigen than effectors. The
effect of downregulation of T cell receptors on T cells, thereby reducing TCR avidity to the
antigen, (“tuning of activation threshold”) has been proposed to occur in some situations, for
example, during maturation of T cells in the thymus (30, 31), and has been documented to occur
during acute infections (32, 33). Our results indicate that CD8+ T cells may also regulate their
avidity for the antigen when antigen load is low. In the acute phase, when antigen is abundant,
CD8+ T cells with lower avidity are selected. In the chronic phase, when antigen is limited,
to efficiently control virus replication CD8+ T cells with higher avidity may become dominant.
Such a selection could occur via at least two mechanisms. First, higher avidity T cells may
be selected during the chronic phase of the infection from the existing pool of effector T cells.
Alternatively, PyV-specific naive CD8+ T cells that have recently emigrated from the thymus
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and have a high affinity for MT389 epitope of PyV could be preferentially activated by the low
amount of antigen present during the infection (19). Given the inability of PyV-specific CD8+
T cells to self-renew during the chronic phase of the infection, the latter mechanism seems more
likely. One potential way of regulating avidity for the antigen is the amount of T-cell receptors
present on the cell surface. A testable prediction of this model result would be a higher number
of T-cell receptors on PyV-specific CD8+ T cells during the chronic phase of the infection as
compared to effectors at the peak of the immune response.
In contrast to the substantial body of work characterizing memory CD8 T cell exhaustion
in high-load chronic viral infections, we know surprisingly little about maintenance of mem-
ory CD8+ T cells to viruses that establish low-level persistent infection. Persistent viremia
(i.e., high-load persistent infection) is associated with a number of infections of global import,
including HIV, HCV, and HBV. In mice, infection by high replicating strains of LCMV (e.g.,
clone 13 or DOCILE) has been the principal animal model for high-load persistent infection. In
this setting, LCMV-specific CD8+ T cells progressively accumulate defects in effector function
and replication potential and are then deleted, a phenomenon called “exhaustion” (2, 34, 35).
The high antigenic burden and duration associated, for example, with HIV infection also drive
virus-specific CD8+ T cells to exhaustion, which is generally considered to be a prelude to
viral persistence (10, 36). T cell exhaustion, however, is at odds to situations involving low-
load persistent viral infections (e.g., γHV-68, and PyV in mice) where the majority of CD8+
T cell functions as measured in ex vivo assays are not compromised and stable numbers of
virus-specific T cells are maintained (37, 38, 39, 40). Here we further demonstrate that the in
vivo killing efficacy of PyV-specific CD8+ T cells in the chronic phase of the infection is only
two-fold lower than that of cells in the acute phase arguing that CD8+ T cells can maintain
their in vivo effector functions long since the primary phase of a persistent infection (Figure 2).
In our previous study by adoptively transferring different numbers of LCMV-specific effector
and memory CD8+ T cells, we found that per cell killing efficacy of memory cells decreased with
the number of transferred cells. We conjectured that this effect could arise due to competition
between LCMV-specific memory CD8+ T cells in the white pulp of the spleen for the access to
targets (8). For PyV infection, we do not know if the two fold reduced killing efficacy of CD8+
T cells in the chronic phase of the infection is also due to localization of these cells in the white
pulp of the spleen.
We have found that killing efficacy of PyV-specific CD8+ T cells depended strongly on the
peptide concentration used to pulse targets. To kill a peptide-pulsed target, a CD8+ T cell
has to accomplish two tasks: find the target and deliver the lethal hit. It is unclear which of
these two processes is the limiting step in the killing of targets. Additional studies including
those looking at the process of killing of targets by effector T cells in vivo (e.g., (41)) will be
necessary to investigate this issue further.
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Overall, our analysis suggests that PyV-specific CD8+ T cells are highly efficient in vivo
killers of peptide-pulsed targets. However, it is unknown if these T cells are also good killers
of cells naturally infected with PyV. Also, it is not known if the killing efficacy of PyV-specific
T cells depends on the tissue in which killing is measured. Finally, by combining the measured
dynamics of viral load in tissues, PyV-specific T cell response and killing efficacy of T cells, it
will be important to investigate whether CD8+ T cells are mainly responsible for the decline on
PyV load during acute phase of the infection. Addressing these issues will a subject of future
research.
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List of Figures
1 Estimating the efficacy of MT389-specific CD8+ T cells at killing targets, pulsed
with a high concentration of the peptide (≥ 1 µM), from the time series data.
We fit the model prediction on the total number of unpulsed targets in the
spleen (panel A, see eqn. (1)) or the ratio of the frequency of peptide-pulsed
to unpulsed targets R (panel B, see eqn. (3)) to the data during acute (•) or
chronic (N) phases of the PyV infection of mice. Parameters providing the best
fit of the model to the data are given in Table 1. Recruitment of targets into the
spleen occurred similarly during the acute and chronic phases of the infection
(χ22 = 1.80, p = 0.41). The half-life time of peptide-pulsed targets at the peak of
the MT389-specific CD8+ T cell response is only 15 minutes, while during the
chronic phase, half of MT389-expressing targets were eliminated in 47 minutes. 7
2 The per capita killing efficacy of PyV-specific CD8+ T cells does not change
during the chronic phase of the infection. We estimate the killing efficacy of
MT389-specific CD8+ T cells from the cytotoxicity assay by normalizing the
death rate of peptide-pulsed targets Kmax by the average frequency of epitope-
specific CD8+ T cells in the spleen (see Materials and Methods). Bars show the
average estimate per time point. Regression slope is not significantly different
from zero (F-test, p = 0.17 with one outlier with a low estimate for kmax re-
moved). The independence of the killing efficacy of CD8+ T cells in the chronic
phase of the infection from the time since infection was further confirmed by
fitting longitudinal killing data (as in Figure 1B) as the fit was not significantly
improved by assuming that killing efficacy was different for different days during
the chronic phase of the infection (F-test for nested models, F4,16 = 2.06, p = 0.13). 9
3 Estimating the killing efficacy of the PyV-specific CD8+ T cells in acute and
chronic phases of the infection from single measurements of killing. Points rep-
resent the maximal killing efficacy of MT389-specific CD8+ T cells, estimated
for individual mice, and horizontal lines are averages for a given peptide concen-
tration. Solid lines show the fits of a Hill function given in eqn. (6) with n = 1 to
the estimated killing efficacies. The estimated parameters are: kˆ = 4.34 min−1,
h = 0.12 µM (acute) and kˆ = 1.91 min−1, h = 0.008 µM (chronic). Differences
in kˆ and h for cells in the acute and chronic phases of the infection remained if
we used the minimal estimate of the killing efficacy (results not shown) . . . . . 10
18
4 Estimating the efficacy of PyV-specific CD8+ T cells at killing target cells, pulsed
with different concentrations of peptide MT389, from the time series data. Points
are the measured ratios of the frequency of peptide-pulsed to unpulsed target
cells, and lines show the fits of the model prediction to the data. The data
were fitted simultaneously assuming that the dependence of the killing efficacy
on the peptide concentration follows a Hill function (see eqn. (6)). Parameters
providing the best fit of the model to data are given in Table 2. Note that to
show the fits and the data, we used different scales on y-axes. . . . . . . . . . . 11
S1 Estimating killing efficacy of MT389-specific CD8+ T cell from a single mea-
surement of in vivo cytotoxicity. Using simple formulas (see Materials and
Methods) we estimate the range (minimal and maximal estimates) for the ef-
ficacy of CD8+ T cells at killing targets pulsed with a high concentration of
the MT389 peptide polyoma virus (≥ 1 µM). Mean and standard deviations
are kmax = 5.74 ± 2.24 min
−1 and kmin = 1.40 ± 0.35 min
−1 (acute phase),
kmax = 2.37 ± 0.87 min
−1 and kmin = 0.89 ± 0.29 min
−1 (chronic phase). Hori-
zontal dashed lines denote the killing efficacy of CD8+ T cells as estimated from
the time series data (see Table 1 in the Main text). . . . . . . . . . . . . . . . . 21
S2 Predicted changes in the normalized killing efficacy of MT389-specific CD8+
T cells in acute (solid lines) or chronic (dashed line) phases of PyV infection.
Killing efficacy is normalized to its maximal value. PyV-specific CD8+ T cells
in the chronic phase of the infection are more efficient killers at low peptide
concentrations. Parameters estimates are given in Table 2. . . . . . . . . . . . . 21
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6 Supplementary Information
6.1 General likelihood approach for data fitting
When a given model is fitted to several datasets simultaneously, it is often assumed that the
distribution of errors of the fit are similar for all datasets. This needs not be true in general. In
those cases, when this is not expected to be a correct assumption, a general likelihood approach
should be used. For our model and the data, the general likelihood of observing the data given
the model prediction on the number of recruited targets S(t) and the ratio of peptide-pulsed
to unpulsed targets R(t) is
L(~S, ~R|~p) =
n∏
i=1
1√
2πs21
e
−(log Si−log S(ti))
2
2s2
1 ×
n∏
i=1
1√
2πs22
e
−(logRi−logR(ti))
2
2s2
2 , (A.1)
where Si and S(ti) are the measured and predicted number of unpulsed targets in the spleen at
time ti after cell transfer, respectively, and Ri and R(ti) are the measured and predicted ratio
of peptide-pulsed to unpulsed targets in the spleen at time ti after cell transfer, respectively, s1
and s2 are the standard deviation of the errors in the recruitment and killing data, respectively,
n is the number of measurements, and ~p is the vector of model parameters to be estimated from
the data. Note that in this example we have log-transformed the data and the model prediction
for both datasets, and in general, one could use different transformations for data fitting.
It is convenient to rewrite eqn. (A.1) in terms of log-likelihood L = log(L):
L(~S, ~R|~p) = −
n∑
i=1
(log Si − log S(ti))
2
2s21
−
n∑
i=1
(logRi − logR(ti))
2
2s22
− n log(s1s2), (A.2)
where we omitted the constant term −n log(2π). Parameters of the model are found by maxi-
mizing the log-likelihood in respect to model parameters and error variances s21 and s
2
2. In the
case when s1 = s2, maximization of eqn. (A.2) will be identical to the commonly used method
of least squares (20).
20
0 50 100 150 200 250
time, min
0
2
4
6
8
10
12
k,
m
in
-
1
~~~~
| |
acute
chronic
Figure S1: Estimating killing efficacy of MT389-specific CD8+ T cell from a single measurement
of in vivo cytotoxicity. Using simple formulas (see Materials and Methods) we estimate the range
(minimal and maximal estimates) for the efficacy of CD8+ T cells at killing targets pulsed with a
high concentration of the MT389 peptide polyoma virus (≥ 1 µM). Mean and standard deviations are
kmax = 5.74 ± 2.24 min
−1 and kmin = 1.40 ± 0.35 min
−1 (acute phase), kmax = 2.37 ± 0.87 min
−1
and kmin = 0.89 ± 0.29 min
−1 (chronic phase). Horizontal dashed lines denote the killing efficacy of
CD8+ T cells as estimated from the time series data (see Table 1 in the Main text).
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Figure S2: Predicted changes in the normalized killing efficacy of MT389-specific CD8+ T cells in
acute (solid lines) or chronic (dashed line) phases of PyV infection. Killing efficacy is normalized to
its maximal value. PyV-specific CD8+ T cells in the chronic phase of the infection are more efficient
killers at low peptide concentrations. Parameters estimates are given in Table 2.
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